Ardelyx Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Ardelyx hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

-0.6%

Rückkaufsrendite

Gesamte Aktionärsrendite	-0.6%
Zukünftige Dividendenrendite	0%
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Jüngste Updates zu Dividenden und Rückkäufen

Keine Aktualisierungen

Recent updates

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Nov 03

Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business

Oct 24

Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?

Aug 25

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Aug 07

Ardelyx Faces Rising Challenges Despite Revenue Growth

Aug 05

Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 04

Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook

Jul 13

Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge

Jul 05

Ardelyx: Strong Execution, Fairly Valued

May 10

Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 04

Ardelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)

May 03

Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing

Apr 17

Ardelyx Shrugs Off 'Mixed' Q4 Earnings

Mar 13

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 24

Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance

Feb 20

Ardelyx's XPHOZAH Still An Afterthought To The Pros

Jan 31

Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement

Jan 10

Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price

Jan 04

Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt

Dec 14

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Aug 03

Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt

Jul 31

Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now

Apr 17

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Mar 30

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Dec 14

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von ARDX in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von ARDX gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Ardelyx Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von ARDX im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (ARDX)	n/a
Untere 25 % des Marktes (US)	1.4%
Markt Top 25 % (US)	4.5%
Branchendurchschnitt (Biotechs)	2.4%
Analystenprognose (ARDX) (bis zu 3 Jahre)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von ARDX im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von ARDX im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von ARDX, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da ARDX keine Ausschüttungen gemeldet hat.

Entdecken Sie dividendenstarke Unternehmen

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2024/12/29 09:14
Aktienkurs zum Tagesende	2024/12/27 00:00
Gewinne	2024/09/30
Jährliche Einnahmen	2023/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

^* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie hier mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf .

Analysten-Quellen

Ardelyx, Inc. wird von 17 Analysten beobachtet. 10 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Timothy Chiang	BTIG
Mara Goldstein	Cantor Fitzgerald & Co.
Louise Chen	Cantor Fitzgerald & Co.

Ardelyx Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

Ardelyx: A Small Bet Its Latest Setback Will Be Temporary

Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It

Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business

Ardelyx, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Ardelyx, Inc. to Present Additional Data Supporting First-In-Class XPHOZAH (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology's Kidney Week

Ardelyx, Inc. Announces Publication of A Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology

Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?

Robbins LLP Informs Ardelyx, Inc. Stockholders of the Class Action

Ardelyx, Inc. Appoints Eric Foster as Chief Commercial Officer

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Ardelyx Faces Rising Challenges Despite Revenue Growth

Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Ardelyx, Inc. Announces Publication of Two Plain Language Summaries from XPHOZAH®? (tenapanor) Clinical Trials in Current Medical Research and Opinion

Ardelyx, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook

Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge

Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell Small Cap Comp Value Index

Ardelyx, Inc. Chooses Not to File for TDAPA to Preserve Patient Access to XPHOZAH

Ardelyx, Inc. Announces Rodriguez Would Resign as Chief Commercial Officer

President recently sold US$246k worth of stock

Insider recently sold US$782k worth of stock

Ardelyx: Strong Execution, Fairly Valued

Consensus revenue estimates increase by 18%

Insider notifies of intention to sell stock

Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date pushed back to 2026

Ardelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)

President notifies of intention to sell stock

Ardelyx, Inc., Annual General Meeting, Jun 14, 2024

Ardelyx, Inc. to Report Q1, 2024 Results on May 02, 2024

Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing

Price target increased by 7.1% to US$13.39

Ardelyx, Inc. Announces the Appointment of Mike Kelliher as Executive Vice President, Corporate Development and Strategy

Insider notifies of intention to sell stock

Ardelyx Shrugs Off 'Mixed' Q4 Earnings

Ardelyx, Inc. announced that it has received $50 million in funding

Consensus EPS estimates fall by 95%, revenue upgraded

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Full year 2023 earnings: EPS misses analyst expectations

Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance

Ardelyx, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Ardelyx's XPHOZAH Still An Afterthought To The Pros

Consensus estimates of losses per share improve by 10%

Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement

Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price

Key Executive notifies of intention to sell stock

Price target increased by 9.5% to US$9.94

Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt

Insider notifies of intention to sell stock

Ardelyx Announces Departure of Geoffrey Block as Board Member

Ardelyx, Inc. Announces XPHOZAH(R) (tenapanor) Now Available in the United States

Consensus revenue estimates increase by 16%

Ardelyx Shares Positive Data from Studies of Xphozah®? (Tenapanor) At Asn Kidney Week 2023

Price target increased by 10% to US$9.36

Ardelyx, Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ardelyx, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Insufficient new directors

Ardelyx, Inc. Shares Positive Data on Symptom Response During Treatment with IBSRELA®? (tenapanor) for IBS-C and Hosts IBS-C Product Theater at ACG 2023

Ardelyx, Inc. Announces FDA Approval of XPHOZAH (tenapanor), a First-In-Class Phosphate Absorption Inhibitor

Ardelyx, Inc. Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

Consensus revenue estimates increase by 17%

New major risk - Shareholder dilution

Price target increased by 7.1% to US$7.58

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt

Ardelyx, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Insider notifies of intention to sell stock

Forecast breakeven date pushed back to 2025

Ardelyx, Inc. Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH(R)

Consensus EPS estimates fall by 47%, revenue upgraded